ABCL

#2041
AbCellera Biologics Inc. Common Shares
3.61
+3.74%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
3.61
3.61
Intervallo Annuale
1.89
6.52
Variazione giornaliera
+3.74%
Variazione Mensile
-10.86%
Variazione di 6 mesi
-18.51%
Variazione Annuale
+32.72%
Chiusura Precedente
3.48
Open
3.61
Bid
Ask
Low
3.61
High
3.61
Volume
47
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.08 B
  • Employee 596
  • Founded 2012
  • CEO Carl Hansen
  • Website www.abcellera.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00LLW2MF2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-6.98
Price to sales ratio
13.6
Dividends per share
—
Dividend yield %
—

AbCellera Biologics Inc

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Notizie